A Phase 1, Single Centre, Single-Blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD7687 After Administration of Multiple Ascending Doses in Overweight to Obese But Otherwise Healthy Male Subjects.

Trial Profile

A Phase 1, Single Centre, Single-Blind, Randomised, Placebo-controlled, Parallel-group Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AZD7687 After Administration of Multiple Ascending Doses in Overweight to Obese But Otherwise Healthy Male Subjects.

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Jan 2016

At a glance

  • Drugs AZD 7687 (Primary)
  • Indications Obesity; Type 2 diabetes mellitus
  • Focus Adverse reactions; Biomarker
  • Most Recent Events

    • 25 Sep 2013 Results presented at the 49th Annual Meeting of the European Association for the Study of Diabetes.
    • 01 Apr 2011 Actual end date (1 Mar 2011) added as reported by ClinicalTrials.gov.
    • 01 Apr 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top